Pancreatic tumours escape from translational control through 4E-BP1 loss

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The eukaryotic translation initiation factor 4E (eIF4E) plays a role in cell transformation when phosphorylated.
• eIF4E activity is regulated by inhibitory eIF4E-binding proteins (4E-BPs), which are targets of the mTOR kinase.
• 4E-BP1 and 4E-BP2 are crucial for the antiproliferative effects of mTOR inhibitors.

Purpose of the Study:

• To investigate the role of 4E-BP1 and 4E-BP2 in pancreatic ductal adenocarcinoma (PDAC).
• To determine the impact of 4E-BP1 downregulation on eIF4E activity and PDAC progression.
• To assess the potential of targeting 4E-BP1/2 pathways for PDAC treatment.

Main Methods:

• Analysis of 4E-BP1 and 4E-BP2 expression in human PDAC and a Kras-driven mouse model.
• Assessment of eIF4E phosphorylation, protein synthesis, and cell proliferation in vitro and in vivo.
• Evaluation of resistance to mTOR inhibitors upon 4E-BP1/2 loss.
• Testing of a novel compound mimicking 4E-BP function.

Main Results:

• Pancreas specifically expresses high levels of 4E-BP1, with 4E-BP2 being nearly undetectable.
• 4E-BP1 expression is lost in over half of human PDAC cases and in a Kras-driven mouse model.
• 4E-BP1 downregulation increases eIF4E phosphorylation, promoting PDAC cell proliferation and tumor growth.
• Loss of 4E-BP1 and 4E-BP2 confers resistance to mTOR inhibitors by maintaining eIF4E phosphorylation and protein synthesis.

Conclusions:

• 4E-BP1 is a critical tumor suppressor in the pancreas, and its loss is a frequent event in PDAC.
• 4E-BP1 downregulation contributes to PDAC pathogenesis by enhancing eIF4E activity and promoting proliferation.
• Combined loss of 4E-BP1 and 4E-BP2 leads to resistance to mTOR-targeted therapies.
• Compounds that mimic 4E-BP function independently of mTOR inhibition show promise for PDAC treatment.